HLN vs KVUE: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
HLN (Haleon plc) and KVUE (Kenvue) share investment themes but are different businesses. The right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme.
HLN vs KVUE: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | HLN | KVUE | What it tells you |
|---|---|---|---|
| Market cap | $44.55B | $36.32B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 16.41 | 15.26 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 20.67 | 21.99 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.28 | 0.45 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 56% of range | 80% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.08 | 3.44 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how HLN and KVUE affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HLN and KVUE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HLN and KVUE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Haleon plc (HLN) do?
Haleon plc is one of the world's largest standalone consumer-health companies, created when GSK demerged its consumer division in 2022. It sells everyday over-the-counter products across five categories: Oral Health (Sensodyne, parodontax, Polident), Pain Relief (Advil, Panadol, Voltaren, Excedrin), Respiratory Health (Theraflu, Otrivin), Vitamins, Minerals and Supplements (Centrum, Emergen-C), and Digestive Health and Therapeutic Skin Health (Tums, Fenistil). The company generated roughly 11 billion pounds (about ~$14 billion) of revenue in 2025 and about 11.15 billion pounds over the twelve months to June 2026, and holds leading or top-tier positions in many of its categories, which gives it pricing power and broad global distribution across pharmacy, grocery, and e-commerce channels.
What does Kenvue (KVUE) do?
Kenvue is the world's largest pure-play consumer health company, spun off from Johnson & Johnson in 2023, and it is now in the process of being acquired by Kimberly-Clark, the maker of Huggies, Kleenex, and Kotex. The two companies signed a merger agreement on November 2, 2025 under which each Kenvue share is to be converted into $3.50 in cash plus 0.14625 of a Kimberly-Clark share, a combination valued at about $48.7 billion when it was announced. In October 2026 the European Commission approved the deal on condition that Kimberly-Clark sell its Kotex, Camelia, and Record feminine-hygiene brands in the European Economic Area (to Dilek Grup), and in August 2026 Kenvue agreed to sell its feminine-care business in Brazil to Essity for about $284 million, a sale Brazil's competition authority has cleared. On September 28, 2026 Kimberly-Clark launched exchange offers for up to $7.0 billion of Kenvue notes, conditioned on the merger, which it expects to complete in the fourth quarter of calendar 2026.
HLN vs KVUE: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- HLN drivers: Oral Health leadership; Margin expansion and cash returns.
- KVUE drivers: What holders receive at closing; Regulatory path and timing.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Organic growth has run at the low end of category norms (about 3% in 2025), pressured by a weak cold and flu season and soft North American consumer confidence, and J.P. For KVUE, the main risks are now deal risks.
HLN or KVUE: which should you pick?
HLN vs KVUE: the full fundamentals
HLN. Haleon trades at about 20 times trailing and 16 times forward earnings, broadly in line with large consumer-staples peers, which prices in its defensive, cash-generative profile rather than a growth premium. Management guides to 3-5% organic revenue growth for 2026, but analyst tracking points to the bottom of that range, and the five covering analysts in the US data carry a mean ADR target near $11.93. The Q3 trading update on October 29, 2026 is the next read; figures are approximate and vary with currency and reporting conventions for the ADR.
KVUE. Kenvue no longer trades on its own fundamentals: with a signed merger agreement and conditional EU approval, the KVUE price reflects $3.50 of cash plus 0.14625 of a Kimberly-Clark share, minus a discount for time and the chance the deal fails. The trailing and forward multiples above describe the business Kimberly-Clark is buying rather than what drives the stock day to day.
Headline figures (approximate, October 2026): HLN shows revenue (ttm) ~£11.15B (FY2025 ~£11.0B, ~$14B), q2 2026 revenue ~£2.75B (latest-quarter growth ~2.2%), margins (ttm) ~66% gross, ~24% operating, ~15% net, net income (ttm) ~£1.6B; KVUE shows deal consideration (per kvue share) $3.50 cash + 0.14625 KMB shares, expected closing Q4 2026 (per Kimberly-Clark), revenue (ttm) ~$15.4 billion (Q2 up ~3% YoY), net income (ttm) ~$1.66 billion.
The bottom line: HLN vs KVUE
HLN and KVUE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HLN and KVUE exposure against your real portfolio. It is not an investment adviser.
Wondering how HLN or KVUE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Haleon plc with AI
Connect the broker you already use and ask Walnut's AI how HLN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between HLN and KVUE?
+
Haleon plc is one of the world's largest standalone consumer-health companies, created when GSK demerged its consumer division in 2022. Kenvue is the world's largest pure-play consumer health company, spun off from Johnson & Johnson in 2023, and it is now in the process of being acquired by Kimberly-Clark, the maker of Huggies, Kleenex, and Kotex. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is HLN or KVUE the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, HLN or KVUE?
+
On forward P/E (as of October 2026), HLN trades at 16.41x and KVUE at 15.26x, so KVUE is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both HLN and KVUE?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of HLN vs KVUE?
+
HLN: Organic growth has run at the low end of category norms (about 3% in 2025), pressured by a weak cold and flu season and soft North American consumer confidence, and J.P. Morgan's tracking puts 2026 at the bottom of the 3-5% guidance range again, so a slow-growth profile is a persistent concern; a reset of the 4-6% medium-term target in February 2027 is a live possibility. The Q4 outlook depends on the cold and flu season. The US pain market has been weak, weighing on Advil despite share gains. Haleon competes against far larger, deeper-pocketed rivals, faces private-label pressure, and carries meaningful debt from its demerger (about 8.3 billion pounds against roughly 0.8 billion of cash). As a UK-based company reporting in pounds, ADR holders are exposed to currency swings, and regulatory or product-liability issues in over-the-counter categories are an ongoing tail risk. KVUE: The main risks are now deal risks. Closing could be delayed or fail if remaining regulatory conditions are not met, and a failed deal would likely send KVUE back toward a standalone valuation. Because most of the consideration is Kimberly-Clark stock, a fall in KMB shares directly lowers what a Kenvue holder receives; Kimberly-Clark shares had fallen about 13% according to an October 2026 report. The combined company takes on Kenvue's inherited litigation, including Tylenol and talc-related claims, plus integration risk and added debt from the cash portion. Until closing, Kenvue's own operations still carry private-label competition, input-cost inflation, and currency exposure, and its latest quarter showed only about 3% revenue growth with EPS slightly below estimates.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell HLN or KVUE; figures are approximate and dated (as of October 2026). Verify current data before investing.